Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US ...

The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer ...

FRANKFURT (REUTERS) -German healthcare and materials group Merck KGaA said on Monday it struck a deal to acquire U.S. biotech ...

Merck KGaA acquires SpringWorks Therapeutics for $3.9B to enhance its cancer drug portfolio, boosting revenue growth and ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement ...

In a press release, Merck KGaA CEO and chair of the executive board Belen Garijo said, “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck KGaA, ...

Merck KGaA’s long courtship of SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the ...

NEW YORK/FRANKFURT, April 28 (Reuters) - Germany's Merck KGaA (MRCG.DE), opens new tab has struck a deal to buy U.S. biotech company SpringWorks Therapeutics (SWTX.O), opens new tab for an equity ...